AngioDynamics (ANGO) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business transformation and strategy

• Transitioned from a stable, legacy-focused company to a high-growth, innovation-driven portfolio over the past five years.

• Divested three non-core businesses and made a key acquisition to focus on cardiovascular and cancer markets.

• Med Tech segment operates in high-growth cardiovascular and cancer markets with innovative technologies and proven clinical outcomes.

• Med Device segment provides stable earnings and funds Med Tech investments, supporting overall growth.

• Med tech revenue share increased from 17% to 43% of total revenue in recent quarters.

Product innovation and clinical advancements

• NanoKnife received FDA approval for intermediate-risk prostate cancer, with strong clinical results and CPT code reimbursement effective January 2026.

• AlphaVac and AngioVac products address the growing PE and thrombectomy markets, with AlphaVac showing superior efficiency and effectiveness.

• Auryon Atherectomy System, acquired in 2019, has treated over 100,000 patients and surpassed $150M in cumulative sales since 2020 launch.

• Ongoing clinical trials and regulatory milestones include AlphaVac PE FDA and CE Mark, Auryon PAD CE Mark, and NanoKnife CPT code and prostate tissue indication.

• Combined med tech growth areas (NanoKnife, AlphaVac, Auryon) grew 16% year-over-year in the first six months.

Market opportunities and growth drivers

• Cardiovascular disease and cancer represent large, underpenetrated markets with significant growth potential.

• Mechanical thrombectomy for VTE and DVT is expected to grow 16–20% in 2025, with current penetration below 25%.

• Focal therapy for prostate cancer is less than 7% penetrated, with incidence projected to double by 2040.

• Market development and education are key to expanding adoption in both oncology and cardiovascular segments.

• Structural heart and PCI market dynamics may increase demand for laser atherectomy and AngioVac technologies.